Skip to main content
Quest Diagnostics

Correlates of Immunity in SARS-CoV-2 Post-Vaccine Infectious in the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study

IDWeek 2022

Washington, DC, October 19 - 23 , 2022

Poster presentation: Correlates of immunity in SARS-CoV-2 post-vaccine infectious in the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study

Authors: Goguet E, Weiss CD, Olsen CH, Powers JH III, Coggins SA, Tribble DR, Davies J, Meyer WA, Ansari S, Illinik L, Lusvarghi S, Sanchez Edwards M, Jackson-Thompson BM, Hollis-Perry M, Pollet S, Wang G, Alcorta Y, Wong MA, Saunders D, Mohammed R, Ortega O, Parmelee E, Lindrose AR, Haines-Hull H, Moser MS, Samuels EC, Tso MS, Graydon E, Malloy AM, Schully KL, Burgess TH, Broder CC, Laing ED, Mitre E

Specialties: Infectious Disease, Immunology, COVID-19

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.